PMID- 38140798
OWN - NLM
STAT- MEDLINE
DCOM- 20240308
LR  - 20240320
IS  - 1988-9518 (Electronic)
IS  - 0214-3429 (Print)
IS  - 0214-3429 (Linking)
VI  - 37
IP  - 2
DP  - 2024 Apr
TI  - Safety of fluoroquinolones.
PG  - 127-133
LID - barberan22dec2023 [pii]
LID - 10.37201/req/143.2023 [doi]
AB  - Fluoroquinolones (FQs) are one of the most commonly prescribed classes of 
      antibiotics. Although they were initially well tolerated in randomized clinical 
      trials, subsequent epidemiological studies have reported an increased risk of 
      threatening, severe, long-lasting, disabling and irreversible adverse effects 
      (AEs), related to neurotoxicity and collagen degradation, such as tendonitis, 
      Achilles tendon rupture, aortic aneurysm, and retinal detachment. This article 
      reviews the main potentially threatening AEs, the alarms issued by regulatory 
      agencies and therapeutic alternatives.
CI  - (c)The Author 2023. Published by Sociedad Espanola de Quimioterapia. This article 
      is distributed under the terms of the Creative Commons Attribution-NonCommercial 
      4.0 International (CC BY-NC 
      4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
FAU - Barberan, J
AU  - Barberan J
AD  - Jose Barberan, Hospital Universitario HM Monteprincipe, Facultad HM Hospitales de 
      Ciencias de la Salud, Universidad Camilo Jose Cela, Madrid, Spain. 
      jose.barberan@ucjc.edu.
FAU - de la Cuerda, A
AU  - de la Cuerda A
FAU - Tejeda Gonzalez, M I
AU  - Tejeda Gonzalez MI
FAU - Lopez Aparicio, A
AU  - Lopez Aparicio A
FAU - Monfort Vinuesa, C
AU  - Monfort Vinuesa C
FAU - Ramos Sanchez, A
AU  - Ramos Sanchez A
FAU - Barberan, L C
AU  - Barberan LC
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231222
PL  - Spain
TA  - Rev Esp Quimioter
JT  - Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola 
      de Quimioterapia
JID - 9108821
RN  - 0 (Fluoroquinolones)
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Humans
MH  - *Fluoroquinolones/adverse effects
MH  - Anti-Bacterial Agents/adverse effects
MH  - *Tendinopathy/chemically induced
PMC - PMC10945095
OTO - NOTNLM
OT  - Fluoroquinolones
OT  - adverse effects
OT  - aortic aneurism
OT  - dysglycemia
OT  - neuropathy
OT  - tendon rupture
COIS- JB have received honoraria for lectures and advisory boards for Pfizer, Wyeth, 
      Merck, Angelini, Menarini, Meiji Pharma Spain, Shionogi and Gilead. Rest of 
      authors declare no conflict of interest.
EDAT- 2023/12/23 12:44
MHDA- 2024/03/08 06:43
PMCR- 2024/01/01
CRDT- 2023/12/23 03:04
PHST- 2024/03/08 06:43 [medline]
PHST- 2023/12/23 12:44 [pubmed]
PHST- 2023/12/23 03:04 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - barberan22dec2023 [pii]
AID - revespquimioter-37-127 [pii]
AID - 10.37201/req/143.2023 [doi]
PST - ppublish
SO  - Rev Esp Quimioter. 2024 Apr;37(2):127-133. doi: 10.37201/req/143.2023. Epub 2023 
      Dec 22.